Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice
Phase II Study of Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice
Status: Archived
Seattle Cancer Care Alliance
962
mi
from 91732
Seattle, WA
Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice
Phase II Study of Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice
Status: Archived
Updated: 1/1/1970
Seattle Cancer Care Alliance
962
mi
from 91732
Seattle, WA
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Rocky Mountain Cancer Center
818
mi
from 91732
Denver, CO
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Updated: 1/1/1970
Rocky Mountain Cancer Center
818
mi
from 91732
Denver, CO
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Virginia Oncology Associates
2345
mi
from 91732
Elizabeth City, NC
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Updated: 1/1/1970
Virginia Oncology Associates
2345
mi
from 91732
Elizabeth City, NC
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Northwest Cancer Specialist
840
mi
from 91732
Vancouver, WA
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Updated: 1/1/1970
Northwest Cancer Specialist
840
mi
from 91732
Vancouver, WA
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Texas Oncology- Sammons CC
1225
mi
from 91732
Dallas, TX
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Updated: 1/1/1970
Texas Oncology- Sammons CC
1225
mi
from 91732
Dallas, TX
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Texas Oncology, P.A. - Bedford
1203
mi
from 91732
Bedford, TX
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Updated: 1/1/1970
Texas Oncology, P.A. - Bedford
1203
mi
from 91732
Bedford, TX
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Texas Oncology-Central Austin Cancer Center
1209
mi
from 91732
Austin, TX
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Updated: 1/1/1970
Texas Oncology-Central Austin Cancer Center
1209
mi
from 91732
Austin, TX
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Texas Oncology-Tyler
1315
mi
from 91732
Tyler, TX
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Updated: 1/1/1970
Texas Oncology-Tyler
1315
mi
from 91732
Tyler, TX
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Virginia Oncology Assoc.
2341
mi
from 91732
Norfolk, VA
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Updated: 1/1/1970
Virginia Oncology Assoc.
2341
mi
from 91732
Norfolk, VA
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Northwest Cancer Specialists at Vancouver Cancer Center
832
mi
from 91732
Vancouver, WA
Triple Negative Breast Cancer Biomarker Study
Triple Negative Breast Cancer Biomarker Study
Status: Archived
Updated: 1/1/1970
Northwest Cancer Specialists at Vancouver Cancer Center
832
mi
from 91732
Vancouver, WA
International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients
Pilot Survey to Assess International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients at Memorial Sloan-Kettering Cancer Center
Status: Archived
Memorial Sloan Kettering
2434
mi
from 91732
New York City, NY
International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients
Pilot Survey to Assess International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients at Memorial Sloan-Kettering Cancer Center
Status: Archived
Updated: 1/1/1970
Memorial Sloan Kettering
2434
mi
from 91732
New York City, NY
Reducing Breast Cancer Recurrence With Weight Loss
Reducing Breast Cancer Recurrence With Weight Loss: A Vanguard Trial
Status: Archived
University of Alabama at Birmingham
1785
mi
from 91732
Birmingham, AL
Reducing Breast Cancer Recurrence With Weight Loss
Reducing Breast Cancer Recurrence With Weight Loss: A Vanguard Trial
Status: Archived
Updated: 1/1/1970
University of Alabama at Birmingham
1785
mi
from 91732
Birmingham, AL
Reducing Breast Cancer Recurrence With Weight Loss
Reducing Breast Cancer Recurrence With Weight Loss: A Vanguard Trial
Status: Archived
Moores Cancer Center
99
mi
from 91732
La Jolla, CA
Reducing Breast Cancer Recurrence With Weight Loss
Reducing Breast Cancer Recurrence With Weight Loss: A Vanguard Trial
Status: Archived
Updated: 1/1/1970
Moores Cancer Center
99
mi
from 91732
La Jolla, CA
Reducing Breast Cancer Recurrence With Weight Loss
Reducing Breast Cancer Recurrence With Weight Loss: A Vanguard Trial
Status: Archived
University of Colorado, Boulder
810
mi
from 91732
Boulder, CO
Reducing Breast Cancer Recurrence With Weight Loss
Reducing Breast Cancer Recurrence With Weight Loss: A Vanguard Trial
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
810
mi
from 91732
Boulder, CO
Reducing Breast Cancer Recurrence With Weight Loss
Reducing Breast Cancer Recurrence With Weight Loss: A Vanguard Trial
Status: Archived
Washington University
1569
mi
from 91732
St. Louis, MO
Reducing Breast Cancer Recurrence With Weight Loss
Reducing Breast Cancer Recurrence With Weight Loss: A Vanguard Trial
Status: Archived
Updated: 1/1/1970
Washington University
1569
mi
from 91732
St. Louis, MO
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
20
mi
from 91732
Los Angeles, CA
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
20
mi
from 91732
Los Angeles, CA
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
University of Chicago
1730
mi
from 91732
Chicago, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
University of Chicago
1730
mi
from 91732
Chicago, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Decatur Memorial Hospital Cancer Care Institute
1645
mi
from 91732
Decatur, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Decatur Memorial Hospital Cancer Care Institute
1645
mi
from 91732
Decatur, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
North Shore University Health Systems
1728
mi
from 91732
Evanston, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
North Shore University Health Systems
1728
mi
from 91732
Evanston, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Infuscience
2272
mi
from 91732
Annandale, VA
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Infuscience
2272
mi
from 91732
Annandale, VA
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Cardinal Bernardin Cancer Center at Loyola University Medical Center
1718
mi
from 91732
Maywood, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Cardinal Bernardin Cancer Center at Loyola University Medical Center
1718
mi
from 91732
Maywood, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Illinois CancerCare-Peoria
1618
mi
from 91732
Peoria, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Illinois CancerCare-Peoria
1618
mi
from 91732
Peoria, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Central Illinois Hematology Oncology Center
1608
mi
from 91732
Springfield, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Central Illinois Hematology Oncology Center
1608
mi
from 91732
Springfield, IL
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Fort Wayne Medical Oncology and Hematology
1854
mi
from 91732
Fort Wayne, IN
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Fort Wayne Medical Oncology and Hematology
1854
mi
from 91732
Fort Wayne, IN
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Community Howard Regional Health
1797
mi
from 91732
Kokomo, IN
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Community Howard Regional Health
1797
mi
from 91732
Kokomo, IN
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
CCOP, Moses Cone Health System-Regional CA Cntr
2152
mi
from 91732
Greensboro, NC
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
CCOP, Moses Cone Health System-Regional CA Cntr
2152
mi
from 91732
Greensboro, NC
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Greenebaum Cancer Center - University of Maryland
2301
mi
from 91732
Baltimore, MD
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Greenebaum Cancer Center - University of Maryland
2301
mi
from 91732
Baltimore, MD
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2302
mi
from 91732
Baltimore, MD
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2302
mi
from 91732
Baltimore, MD
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
2575
mi
from 91732
Boston, MA
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
2575
mi
from 91732
Boston, MA
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
University of Michigan Comprehensive Cancer Center
1932
mi
from 91732
Ann Arbor, MI
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Oncology Care Associates, PLLC
1790
mi
from 91732
Saint Joseph, MI
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Oncology Care Associates, PLLC
1790
mi
from 91732
Saint Joseph, MI
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
David Fivenson, M.D. Dermatology, PLLC
1928
mi
from 91732
Ann Arbor, MI
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
David Fivenson, M.D. Dermatology, PLLC
1928
mi
from 91732
Ann Arbor, MI
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Hulston Cancer Center at Cox Medical Center South
1399
mi
from 91732
Springfield, MO
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Hulston Cancer Center at Cox Medical Center South
1399
mi
from 91732
Springfield, MO
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
2404
mi
from 91732
Basking Ridge, NJ
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
2404
mi
from 91732
Basking Ridge, NJ
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Medical College of Wisconsin
1729
mi
from 91732
Milwaukee, WI
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cancer, or Recurrent Triple-Negative Breast Cancer
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Platinum-Sensitive Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Archived
Updated: 1/1/1970
Medical College of Wisconsin
1729
mi
from 91732
Milwaukee, WI
Tissue Oxygenation Measurements With Modulated Light (S-FLARE)
Tissue Oxygenation Measurements During Plastic Surgery Using Spatially Modulated Light (S-FLARE)
Status: Archived
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
Tissue Oxygenation Measurements With Modulated Light (S-FLARE)
Tissue Oxygenation Measurements During Plastic Surgery Using Spatially Modulated Light (S-FLARE)
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
2578
mi
from 91732
Boston, MA
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer
Status: Archived
University of Colorado, Boulder
810
mi
from 91732
Boulder, CO
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
810
mi
from 91732
Boulder, CO
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer
Status: Archived
Providence Alaska Medical Center
2341
mi
from 91732
Anchorage, AK
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Providence Alaska Medical Center
2341
mi
from 91732
Anchorage, AK
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer
Status: Archived
The West Clinic, PC
1597
mi
from 91732
Memphis, TN
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
The West Clinic, PC
1597
mi
from 91732
Memphis, TN
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Birmingham Hematology and Oncology Associates, LLC
1785
mi
from 91732
Birmingham, AL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Birmingham Hematology and Oncology Associates, LLC
1785
mi
from 91732
Birmingham, AL
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Highlands Oncology Group
1355
mi
from 91732
Springdale, AR
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Highlands Oncology Group
1355
mi
from 91732
Springdale, AR
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Clopton Clinic Hematology/Oncology
1547
mi
from 91732
Jonesboro, AR
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Clopton Clinic Hematology/Oncology
1547
mi
from 91732
Jonesboro, AR
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Hematology Oncology Services of Arkansas
1460
mi
from 91732
Little Rock, AR
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Hematology Oncology Services of Arkansas
1460
mi
from 91732
Little Rock, AR
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Compassionate Cancer Care Medical Group, Inc.
30
mi
from 91732
Corona, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Compassionate Cancer Care Medical Group, Inc.
30
mi
from 91732
Corona, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Wilshire Oncology Medical Group, Inc.
15
mi
from 91732
Pomona, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Wilshire Oncology Medical Group, Inc.
15
mi
from 91732
Pomona, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Loma Linda Medical Center
43
mi
from 91732
Loma Linda, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Loma Linda Medical Center
43
mi
from 91732
Loma Linda, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Comprehensive Cancer Center
85
mi
from 91732
Palm Springs, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Comprehensive Cancer Center
85
mi
from 91732
Palm Springs, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Sutter Health Cancer Research Group
368
mi
from 91732
Greenbrae, CA
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients With Newly Diagnosed HER2-negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Sutter Health Cancer Research Group
368
mi
from 91732
Greenbrae, CA